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SMPDL3b modulates insulin receptor signaling in
diabetic kidney disease
A. Mitrofanova1,2,3, S.K. Mallela1,2, G.M. Ducasa1,2,4, T.H. Yoo1,2,5, E. Rosenfeld-Gur6, I.D. Zelnik6, J. Molina1,2,
J. Varona Santos1,2, M. Ge1,2,4, A. Sloan1,2, J.J. Kim1,2, C. Pedigo1,2,7, J. Bryn1,2, I. Volosenco 1,2,8, C. Faul1,2,9,
Y. H. Zeidan2,10,11, C. Garcia Hernandez1,2,10, A.J. Mendez12, I. Leibiger13, G.W. Burke3,12, A.H. Futerman6,
L. Barisoni14, Y. Ishimoto 15,16, R. Inagi 15,16, S. Merscher1,2 & A. Fornoni1,2
Sphingomyelin phosphodiesterase acid-like 3b (SMPDL3b) is a lipid raft enzyme that reg-
ulates plasma membrane (PM) ﬂuidity. Here we report that SMPDL3b excess, as observed in
podocytes in diabetic kidney disease (DKD), impairs insulin receptor isoform B-dependent
pro-survival insulin signaling by interfering with insulin receptor isoforms binding to caveolin-
1 in the PM. SMPDL3b excess affects the production of active sphingolipids resulting in
decreased ceramide-1-phosphate (C1P) content as observed in human podocytes in vitro and
in kidney cortexes of diabetic db/db mice in vivo. Podocyte-speciﬁc Smpdl3b deﬁciency in db/
db mice is sufﬁcient to restore kidney cortex C1P content and to protect from DKD. Exo-
genous administration of C1P restores IR signaling in vitro and prevents established DKD
progression in vivo. Taken together, we identify SMPDL3b as a modulator of insulin signaling
and demonstrate that supplementation with exogenous C1P may represent a lipid therapeutic
strategy to treat diabetic complications such as DKD.
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Sphingolipids and cholesterol are critical components of theeukaryotic plasma membrane (PM), where they serve asmajor mediators of lipid-signaling regulating multiple cel-
lular functions1. We have identiﬁed sphingomyelin phospho-
diesterase acid-like 3b (SMPDL3b) as a lipid raft enzyme that
regulates integrin activation, cell migration, and cell survival in
podocytes, which are terminally differentiated and specialized
cells of the kidney glomerulus2,3. Others have demonstrated an
important role of SMPDL3b in affecting membrane lipid com-
position and ﬂuidity in macrophages4. Although the crystal
structure of SMPDL3b was recently reported5, the speciﬁcity of its
phosphodiesterase activity and the possibility of other lipid
modifying functions of SMPDL3b have not been investigated yet.
Ceramide is the centerpiece of the sphingolipid metabolic
pathway, where it serves as substrate for the generation of
ceramide-1-phosphate (C1P) and sphingosine 1-phosphate (S1P)
6. C1P and S1P are bioactive sphingolipids regulating important
processes, such as cell survival and inﬂammatory responses. S1P
can be cleaved by S1P lyase, and S1P excess due to a genetic
deﬁciency of S1P lyase was recently found to be associated with
adrenal insufﬁciency, nephrotic syndrome, and ichthyosis7–9. In
contrast, while reduction of biologically active C1P has been
linked to apoptosis and altered inﬂammatory signaling, little is
known about the metabolic or signaling pathways that are con-
trolled by C1P and that regulate C1P content.
The overall goal of this study is to determine if SMPDL3b may
affect the availability of biologically active lipids and alter the
assembly of protein complexes in lipid raft domains thus inter-
fering with physiological signaling. Among signaling complexes
located in raft domains that are heavily dependent on the PM
lipid composition, we are focused on the insulin receptor (IR)-
signaling complex for several reasons: (1) IR signaling is a key
modulator of podocyte function10–12; (2) SMPDL3b is strongly
upregulated in glomeruli of patients with insulin resistance and
diabetic kidney disease (DKD)3; (3) IR exists in two isoforms
which are characterized by distinct afﬁnities for lipid raft
domains13 and which are differentially expressed in various cell
types suggesting distinct functions. We therefore tested the
hypothesis that SMPDL3b affects the generation of sphingolipids
involved in the regulation of IR signaling.
Terminally differentiated human podocytes are utilized as a
model system to study in vitro whether SMPDL3b differentially
affects IR isoform A (IRA) or IR isoform B (IRB) complex for-
mation with caveolin-1 and IR-dependent signaling. A diabetic
db/db mouse model with podocyte-speciﬁc deletion of Smpdl3b is
used to determine if SMPDL3b deﬁciency protects from experi-
mental DKD. Here we report and discuss that increased expres-
sion of SMPDL3b is associated with deﬁciency of biologically
active C1P in vitro and in vivo. Exogenous C1P supplementation
is sufﬁcient to restore insulin signaling in SMPDL3b over-
expressing (SMP OE) cells in vitro and to improve proteinuria in
DKD in vivo. Our ﬁndings shed some light on the complexity of
IR signaling, demonstrate an important role of SMPDL3b in the
modulation of insulin signaling, and provide the ﬁrst evidence
that biologically active lipids, such as C1P may represent treat-
ment options for complications of diabetes associated with high
cardiovascular morbidity and mortality such as DKD.
Results
SMPDL3b affects the levels of C1P. We previously described
SMPDL3b as an enzyme expressed in podocyte lipid rafts that
might play an important role in the pathogenesis of proteinuric
kidney diseases2,3. Others showed that SMPDL3b functions as a
phosphodiesterase with lipid-modifying properties that negatively
regulates immunity in macrophages4. We ﬁrst aimed at
determining if SMPDL3b also acts as a phosphodiesterase in
human podocytes and found that overexpression of SMPDL3b in
podocytes (SMP OE) is associated with increased cellular phos-
phodiesterase activity, while knockdown of SMPDL3b (siSMP)
resulted in decreased phosphodiesterase activity (Fig. 1a). In
addition to this, the degree of SMPDL3b expression affected the
content of active sphingolipids in podocytes. While the total
sphingomyelin (Fig. 1b) and total ceramide (Fig. 1c) levels
remained unchanged, total C1P levels were signiﬁcantly
decreased in SMP OE podocytes and increased in siSMP podo-
cytes (Fig. 1d) compared to control podocytes (CTRL). To
determine which ceramide species mostly contribute to the
observed changes in C1P levels, liquid chromatography mass
spectrometry (LC–MS) was performed. While human podocytes
mostly express C16:0, C22:0, C24:0, and C24:1 ceramide and
C16:0, C18:0, and C24:0 C1P species, only C16:0 C1P levels were
signiﬁcantly reduced in SMP OE and increased in siSMP podo-
cytes (Supplementary Data 1).
In addition to its phosphodiesterase activity, protein sequence
analysis of SMPDL3b using InterPro protein sequencing analysis
tool, predicted the presence of a phosphatase-like domain. In
order to understand if SMPDL3b may contribute to the decreased
C1P content by converting C1P into ceramide, we utilized an
in vitro assay in HEK293 cells transfected with full-length human
SMPDL3b and found a signiﬁcantly higher conversion of C1P to
ceramide upon SMPDL3b overexpression (Fig. 1e). However,
in vitro enzyme assay determination of SMPDL3b activity with
pure recombinant protein failed to detect phosphatase activity
(Supplementary Fig. 1). While this could be due to the utilization
of a soluble non-GPI-anchored protein or to the absence of an
essential cofactor, we can only conclude that SMPDL3b
contributes to the conversion of C1P into ceramide.
SMPDL3b affects IR signaling. We previously observed that
SMPDL3b is strongly upregulated in glomeruli of patients with
insulin resistance and DKD3. This observation, together with the
ﬁnding that preservation of insulin signaling is a key to protect
podocytes from injury10,12,14,15, prompted us to determine if
SMPDL3b may affect insulin signaling pathways. mRNA
sequence analysis in control and SMP OE podocytes was per-
formed. We found differential expression of 1948 genes
that passed FDR correction in SMP OE podocytes compared to
control (Supplementary Data 2). Using DAVID pathway-
enrichment analysis, we found that 62 signaling pathways are
affected in SMPDL3b overexpression cells (Supplementary
Data 3). Among them, differential expression of genes involved in
the regulation of phosphoinositide 3-kinase and protein kinase B
(PI3K-AKT), sphingolipid signaling, mammalian target of rapa-
mycin (mTOR), and insulin resistance pathways was observed
(Supplementary Data 3). In addition, similar to what was
described in macrophages4, differential regulation of genes
important in innate immunity, involved in the tumor necrosis
factor (TNF), nuclear factor kappa-light-chain-enhancer of acti-
vated B-cells (NFκB) and toll-like receptors (TLRs)-signaling
pathways, was observed (Supplementary Data 3).
We ﬁrst validated mRNAseq ﬁndings at the protein level,
demonstrating that SMP OE cells, unlike siSMP or CTRL
podocytes, are unable to phosphorylate protein kinase B (AKT),
but become responsive to phosphorylate p70S6 kinase (p70S6K)
(Fig. 2a, b) after stimulation with insulin. SMP OE podocytes also
demonstrated increased phosphorylation of eukaryotic transla-
tion initiation factor 4E-binding protein-1 (4EB-P1), a down-
stream target of mTOR signaling, while the phosphorylation of
4EB-P1 was suppressed in siSMP and CTRL podocytes (Fig. 2a,
b). Additionally, kinetics of phosphorylation of AKT, p70S6K, or
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4EB-P1 in response to insulin stimulation demonstrated similar
dynamics between CTRL and siSMP podocytes, while SMP OE
podocytes showed no changes in AKT phosphorylation over time,
but increased phosphorylation of p70S6K and 4EB-P1 (Fig. 2c).
We therefore focused on SMP OE podocytes in subsequent
experiments. The modulation of IR signaling by SMPDL3b in
podocytes was not linked to a change in IR expression (Fig. 2d).
However, subcellular fractionation experiments demonstrated a
decreased presence of IR at the PM in SMP OE podocytes
compared to control podocytes (Fig. 2e), which could at least
partially explain why insulin-stimulated AKT phosphorylation is
impaired. Further experiments using ﬂow cytometry assay
validated our ﬁndings and showed that SMP OE podocytes have
less IR-positive cells (Fig. 2f). The displacement of IR from the
PM was independent of caveolin-1, a lipid raft-associated protein
required for proper insulin signaling14–16, as phosphorylated and
total amounts of caveolin-1 in whole cell lysates (Supplementary
Fig. 2a) and in the PM fraction (Supplementary Fig. 2b) remained
unchanged. The opposite regulation of AKT and p70S6K
phosphorylation after insulin stimulation observed in SMP OE
podocytes prompted us to investigate if SMPDL3b may
contribute to the functional diversiﬁcation of IR isoforms
signaling, as demonstrated in pancreatic beta cells, where IRA,
in which exon 11 is excluded, is a modulator of p70S6K
phosphorylation while IRB is a regulator of AKT phosphoryla-
tion13. More detailed analysis of IR expression revealed that
human podocytes express both IR isoforms17, with IRB being the
dominantly expressed isoform in both SMP OE and control
podocytes (Fig. 2g). As tools to experimentally distinguish
between endogenous IRA and IRB protein expression are not
available, additional experiments in transfected HEK293 cells
were performed to determine whether SMPDL3b differentially
interferes with IRA/IRB signaling.
SMPDL3b competes with binding of IRA and IRB to caveolin-
1. Given that we found a differential regulation of the insulin-
stimulated PI3K-AKT and mTOR-signaling pathways in SMP OE
podocytes, we tested the hypothesis that SMPDL3b over-
expression differentially affects IRA and IRB signaling by inter-
fering with the formation of IRA/caveolin-1 or IRB/caveolin-1
complexes. Immunoprecipitation (IP) experiments of exogenous
proteins co-expressed in HEK293 were performed. We found that
SMPDL3b immunoprecipitates both IR isoforms (Fig. 3a) and
caveolin-1, and the ability to form complexes with IR isoforms
and caveolin-1 was not affected by the utilization of the
SMPDL3b phosphodiesterase mutant SMPDL3b-H135A
(Fig. 3b). Considering that SMPDL3b interacts with IRA, IRB,
and caveolin-1, we investigated if SMPDL3b competes with IR
isoforms to bind caveolin-1 by competitive IP studies in trans-
fected HEK293 cells. We found that SMPDL3b facilitates the
interaction of caveolin-1 and IRA (Fig. 3c, left panel) while
interfering with the ability of IRB to bind caveolin-1 (Fig. 3c, right
panel), even when expressed at low levels. To conﬁrm the
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Fig. 1 SMPDL3b affects the conversion of C1P to ceramide. a Bar graph analysis of phosphodiesterase (PDE) activity in control (CTRL), SMPDL3b
knockdown (siSMP) and SMPDL3b overexpressing (SMP OE) human podocytes. n= 3 independent experiments; *P= 0.039, two-tailed t-test. b Liquid
chromatography mass spectrometry analysis (LC–MS) of total sphingomyelin content in CTRL, siSMP, and SMP OE human podocytes. n= 3 independent
experiments. P= 0.78, F= 0.26, one-way ANOVA. c LC–MS of total ceramide content in CTRL, siSMP, and SMP OE human podocytes. n= 3 independent
experiments. P= 0.78, F= 0.78, one-way ANOVA. d LC–MS of total ceramide-1-phosphate (C1P) content in CTRL, siSMP, and SMP OE human podocytes.
n= 3 independent experiments. *P= 0.045, **P= 0.007, F= 32.58, one-way ANOVA. e C1P phosphatase in vitro assay using increasing amounts
C6-NBD-C1P. n= 2 independent experiments in duplicate; *P < 0.05, ***P < 0.001; two-tailed t-test. Error bars represent standard deviation (SD)
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interaction of SMPDL3b with IRA and IRB ex vivo, endogenous
IP experiments using pooled mouse glomeruli were performed
and showed that SMPDL3b precipitates both IR isoforms and
caveolin-1 (Fig. 3d). While in the absence of SMPDL3b, caveolin-
1 preferentially binds IRB, the presence of SMPDL3b interferes
with the binding of IRB to caveolin-1 and facilitates binding of
IRA to caveolin-1, which is consistent with the observation that
insulin-stimulated AKT phosphorylation is impaired while
p70S6K phosphorylation is augmented in SMP OE podocytes
(Fig. 2a, b). As binding of IR to caveolin-1 is important to pro-
mote insulin signaling14,18–20, our data suggest that SMPDL3b
overexpression may shift IR signaling from IRB-mediated to IRA-
mediated signaling. Next, we tested whether methyl-β-
cyclodextrin (CD), which was found to act as a chemical
caveolin-1 inhibitor21, can restore IRB signaling in SMPDL3b-
overexpressing cells. We found that CD increased AKT phos-
phorylation (Fig. 3e) without affecting p70S6K phosphorylation
(Fig. 3e). Additionally, CD treatment of transfected HEK293 cells
resulted in restored interaction between IRB and caveolin-1 in
presence of SMPDL3b overexpression, while IRA/caveolin-1
interaction was compromised (Fig. 3f). This occurred in asso-
ciation with increased IR and decreased SMPDL3b localization at
the PM (Fig. 3g). While it is not possible to discriminate with this
model if CD differentially affects IRA or IRB localization, the
observed increase in AKT phosphorylation in the absence of
changes in p70S6K phosphorylation suggests that CD primarily
restores the PM localization of IRB.
Podocyte-speciﬁc Smpdl3b-deﬁcient mice have normal kidneys.
The generation of Smpdl3b ﬂoxed mice is described in detail in
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the “Methods” section. To generate podocyte-speciﬁc Smpdl3b-
deﬁcient mice, Smpdl3b-ﬂoxed mice were mated with Podocin-
Cre mice22. A schematic representation of the Smpdl3b wildtype
allele and targeted allele is shown in Fig. 4a. Genotyping was
performed by PCR on genomic DNA isolated from tail biopsies.
Sequences of primers used for genotyping are indicated in Sup-
plementary Table 1. Two primer sets were used, one speciﬁc for
the Podocin-Cre transgene, yielding a 455 bp PCR product and
another set to detect either the Smpdl3b ﬂoxed (237 bp PCR
product) or wildtype allele (315 bp PCR product) (Supplementary
Fig. 3a). To determine if successful Cre-mediated recombination
has occurred, PCR on genomic DNA isolated from glomeruli was
also performed using the primers indicated in Supplementary
Table 1. This PCR will only yield a product (198 bp) if Cre-
mediated recombination has occurred (Supplementary Fig. 3b).
However, a 1075 bp band was also detected which could be
explained by the presence of mesangial and endothelial cells in
glomerular extracts in which Cre-mediated recombination did
not occur. Nevertheless, as expected, the 198 bp PCR product was
only detected when DNA isolated from glomeruli of heterozygous
(Cre+;ﬂ/+) and homozygous (Cre+;ﬂ/ﬂ) mice was used but not
in wildtype mice. We then performed qRT-PCR to determine
Smpdl3b mRNA expression levels in glomeruli isolated from
wildtype and podocyte-speciﬁc Smpdl3b-deﬁcient mice and
demonstrated a 57% reduction of Smpdl3b expression in Cre+;ﬂ/
ﬂ mice (Fig. 4b). As expected, Smpdl3b expression levels in
tubules remained unchanged (Fig. 4c). Similarly, SMPDL3b
protein expression in glomeruli isolated from wildtype (Cre+;
+/+) and podocyte-speciﬁc Smpdl3b-deﬁcient mice showed a
55% reduction in Cre+;ﬂ/ﬂ mice (Fig. 4d) when compared to
wildtype littermates. Finally, SMPDL3b expression levels in
podocyte-speciﬁc Smpdl3b-deﬁcient mice were also found to be
reduced in immunoﬂuorescence staining for SMPDL3b. Synap-
topodin was used as a podocyte-speciﬁc marker (Fig. 4e).
Podocyte-speciﬁc Smpdl3b-deﬁcient mice are viable and
fertile. At the age of 28 weeks Smpdl3b-deﬁcient mice
demonstrated no changes in body weight (Fig. 4f), kidney to
body weight ratio (Fig. 4g), urine albumin to creatinine ratio
(Fig. 4h), blood urine nitrogen (Fig. 4i), serum creatinine
levels (Fig. 4j), or mesangial expansion score (Fig. 4k) when
compared to wildtype mice. Suppression of SMPDL3b
expression in podocyte-speciﬁc Smpdl3b deﬁcient mice was
not sufﬁcient to lead to a change in sphingolipid composition
in kidney cortexes, suggesting that other cell types may
compensate for SMPDL3b deﬁciency in podocytes (Supple-
mentary Fig. 3c–e; Supplementary Data 4).
Smpdl3b-deﬁcient mice are protected from DKD. As podocyte-
speciﬁc Smpdl3b-deﬁcient mice are phenotypically normal, we
next tested if podocyte-speciﬁc deﬁciency of Smpdl3b is sufﬁcient
to protect diabetic mice from DKD. To test this hypothesis,
double knockout mice carrying a mutation in leptin receptor (db/
db) and a podocyte-speciﬁc Smpdl3b deﬁciency (ﬂ/ﬂ) were gen-
erated (Supplementary Fig. 4a). For genotyping, genomic DNA
isolated from tail biopsies and PCR primers for genotyping as
indicated in Supplementary Table 1 were used.
Four groups of mice were utilized: (1) wildtype control mice
(+/+;+/+), n= 10; (2) podocyte-speciﬁc Smpdl3b deﬁcient mice
(ﬂ/ﬂ;+/+), n= 11; (3) diabetic control mice (+/+;db/db), n= 9;
and (4) podocyte-speciﬁc Smpdl3b-deﬁcient diabetic mice (ﬂ/ﬂ;
db/db), n= 9. No changes were found in body weight (Fig. 5a) or
kidney to body weight ratio (Fig. 5b) between +/+;db/db and ﬂ/ﬂ;
db/db mice. At 28 weeks of age, ﬂ/ﬂ;db/db mice showed
signiﬁcantly lower urinary albumin to creatinine ratios (Fig. 5c)
and mesangial expansion (Fig. 5d) compared to +/+;db/db mice,
suggesting a protective effect of the podocyte-speciﬁc deletion of
Smpdl3b in DKD progression in this model. We did not detect
any changes in BUN (two-tail t-test; P= 0.114), serum creatinine
(two-tail t-test; P= 0.466), glycemia (two-tail t-test; P= 0.067), or
liver function (ALT and AST, two-tail t-test; P= 0.634 and P=
0.670, respectively) between double knockout mice and diabetic
mice (Supplementary Table 2), indicating that podocyte-speciﬁc
Smpdl3b deﬁciency does not lead to any renal or hepatic toxicity.
Additionally, no changes were found in total cholesterol or
triglyceride levels between +/+;db/db and ﬂ/ﬂ;db/db mice
(Supplementary Table 2). Because our in vitro data suggested
an important role of SMPDL3b in the generation of ceramide
from C1P, detailed lipidomic analysis of sphingolipids in kidney
cortexes of the double knockout mice was performed using
LC–MS analysis (Supplementary Data 5). Similar to what we
found in SMP OE podocytes (Fig. 1), kidney cortexes from ﬂ/ﬂ;
db/db mice demonstrated no changes in total ceramide (Fig. 5e)
or total sphingomyelin (Fig. 5f) in association with a decreased
C1P content (Fig. 5g). Podocyte-speciﬁc deletion of Smpdl3b in
diabetic mice was sufﬁcient to restore normal C1P levels in
kidney cortex (Fig. 5g). These results support an important role of
SMPDL3b in vivo as an active lipid-modifying enzyme and
outline the importance of podocyte SMPDL3b expression in the
pathogenesis of DKD.
Additionally, podocyte density and apoptosis were assessed by
immunoﬂuorescent labeling using an anti-Wilms’ Tumor 1
(WT1) antibody. WT1-positive nuclei were counted in 20
consecutive glomerular cross-sections per animal as reported11.
Fig. 2 SMPDL3b regulates the insulin-signaling pathway in human podocytes. a Representative Western blot image of main downstream targets of the
insulin receptor signaling in control (CTRL), SMPDL3b knockdown (siSMP) and SMPDL3b overexpressing (SMP OE) podocytes exposed to increasing
concentration of insulin (0, 0.1, 1 nM): phosphorylated (pAKT) and total (tAKT) AKT; phosphorylated (p-p70S6K) and total (t-p70S6K) p70S6K;
phosphorylated (p-4EB-P1) and total (t-4EB-P1) 4EB-P1. b Bar graph analysis of the fold change ratio of pAKT to tAKT (left panel), p-p70S6K to t-p70S6K
(central panel) and p-4EB-P1 to t-4EB-P1 (right panel) in CTRL, siSMP, and SMP OE podocytes. n= 3 independent experiments; *P < 0.05 (when compared
AKT phosphorylation level in insulin treated CTRL cells); ##P= 0.002, #P= 0.011, F= 5.67 (when compared AKT phosphorylation level in insulin-treated
siSMP cells); ***P= 0.0002, ****P < 0.0001, F= 21.47 (when compared p70S6K phosphorylation level in insulin-treated SMP OE cells); $$P= 0.008, $$$
$P < 0.0001, F= 10.09 (when compared 4EB-P1 phosphorylation level in insulin-treated SMP OE cells); one-way ANOVA. n= 3 independent experiments.
c Kinetics of AKT (left panel), p70S6K (central panel), and 4EB-P1 (right panel) phosphorylation in CTRL, siSMP, and SMP OE podocytes treated with 1 nM
of insulin. **P= 0.001, F= 9.31; ##P= 0.0003, F= 12.27; $$P= 0.003, F= 7.84, one-way ANOVA. n= 3. d Western blot and bar graph analysis of insulin
receptor (IR) expression in total lysates of CTRL and SMP OE podocytes; P= 0.448, two-tailed t-test. n= 4 independent experiments. e Western blot and
graph analysis of IR localization at the plasma membrane (PM) in CTRL and SMP OE podocytes. Na/K-ATPase was used as a marker for the PM fraction
and MEK-1/2 was used as a marker of the cytosolic fraction (CYTO); ***P= 0.0004, two-tailed t-test. n= 5 independent experiments. f FACS and related
quantiﬁcation analysis of the insulin receptor expression in CTRL and SMP OE podocytes. Unstained cells were used as a negative control; HEK293 cells
transfected with an insulin receptor overexpressing construct were served as a positive control. A total of 30,000 cells per sample was analyzed; ***P <
0.0001, two-tailed t-test. n= 4 independent experiments. g PCR analysis of the insulin receptor isoform A (IRA) and isoform B (IRB) gene expression in
CTRL, and SMP OE podocytes. Error bars represent standard deviation (SD)
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ﬂ/ﬂ;db/db mice demonstrated preserved podocyte number per
glomerulus when compared to +/+;db/db mice (Fig. 5h) further
supporting a protective effect of decreased podocyte SMPDL3b
expression in DKD. Moreover, electron microscopy analysis
revealed signiﬁcant improvement of podocyte foot process
effacement and reduced glomerular basement membrane
(GBM) thickness in ﬂ/ﬂ;db/db mice compared to +/+;db/db
mice (Fig. 5i) with a tendency to a decreased foot processes width
(Supplementary Fig. 4b). Immunohistochemistry analysis showed
that ﬂ/ﬂ;db/db glomeruli were characterized by increased
phosphorylated AKT compared to +/+;db/db mice (Fig. 5j).
These results prompted us to further investigate the link between
podocyte-speciﬁc SMPDL3b deﬁciency, C1P availability and
insulin signaling in the protection from DKD.
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C1P supplementation restores IR signaling and protects from
DKD. Given our observation that podocyte-speciﬁc Smpdl3b-
deﬁcient diabetic mice are protected from experimental DKD,
and that kidney cortex from db/db mice are characterized by
decreased C1P content (Fig. 5g), we hypothesized that exo-
genous supplementation of C1P may protect from albuminuria
and podocyte injury in DKD. We therefore tested if exogenous
C1P supplementation is sufﬁcient to restore podocyte insulin
signaling in vitro and to protect from DKD in vivo. Control and
SMP OE podocytes were pre-treated with 100 µM of synthetic
C1P C16:0 for 1 h and then stimulated with 1 nM of human
insulin for 30 min. We found that treatment of SMP OE
podocytes with C1P is sufﬁcient to restore AKT phosphoryla-
tion (Ser473) in response to insulin stimulation (Fig. 6a), while
no changes in phosphorylation of p70S6K were observed
(Fig. 6b). Mass spectrometry analysis of ceramide species in
kidney cortex of db/db mice demonstrated that db/db mice
produce signiﬁcantly less C16:0 ceramide compared to het-
erozygous db/+ littermates (Fig. 6c), similarly to what we
showed in SMP OE podocytes (Supplementary Data 1). To
determine whether exogenous C1P administration ameliorates
features of DKD in these mice, 12-week-old db/db mice with
established albuminuria were injected intraperitoneally with 30
mg/kg C16:0 C1P (n= 6) or 0.9% normal saline (n= 6) daily
for 28 days. Heterozygous (db/+) littermates injected with 0.9%
normal saline served as control (n= 6). C1P administration to
diabetic db/db mice with established DKD resulted in sig-
niﬁcant improvement of albuminuria when compared to saline
injected db/db control mice (Fig. 6d). Additionally, db/db mice
treated with C1P demonstrated signiﬁcantly less mesangial
expansion (Fig. 6e). C1P treatment of db/db mice did not
negatively affect kidney function (BUN and serum creatinine),
liver function (serum ALT, AST), or serum lipids (triglyceride
and cholesterol) (Supplementary Table 3). Additionally, no
changes in body weight (Supplementary Fig. 5a) or glycemia
(Supplementary Fig. 5b) were detected. Pathological analysis at
the C1P injection site by standard immunohistochemistry did
not reveal any detectable microscopic change (Supplementary
Fig. 5c). In addition, C1P treatment of db/db mice resulted in
increased podocyte AKT phosphorylation when compared to
db/db normal saline-injected mice (Fig. 6f). To investigate if
observed improvement of the kidney function with exogenous
C1P administration in db/db mice is related to the improve-
ment of glycemic control, we performed intraperitoneal glucose
tolerance test. No changes were found in fasting glycemia
(Fig. 6g, left panel) or intraperitoneal glucose tolerance test
(Fig. 6g, right panel) between saline injected and C1P-treated
db/db mice.
Discussion
Our study identiﬁes SMPDL3b as a sphingolipid-related enzyme
that inﬂuences the content of active lipids and acts as a master
regulator of insulin signaling in lipid raft domains of the PM. Our
ﬁndings suggest a model by which SMPDL3b may affect podocyte
function and survival, where excessive SMPDL3b expression may
cause the displacement of IR from caveolin-1-rich domain in a
C1P-dependent manner, resulting in impaired ability to phos-
phorylate AKT thus promoting podocyte injury in vitro and
development of DKD in vivo.
We ﬁrst conﬁrmed the presence of increased phosphodiester-
ase activity in SMP OE podocytes when compared to wildtype,
which was expected given the homology of SMPDL3b with acid
sphingomyelinase and the recently reported crystallographic
structure5. Unexpectedly, this activity was not associated with a
reduction of the sphingomyelin content and increased ceramide
production in podocytes, which prompted us to utilize a large-
scale lipidomic approach to identify additional sphingolipid
species that may be affected by SMPDL3b. Among the different
lipid species, a reduction of C1P species was observed, pre-
dominantly C16:0 C1P. Interestingly, the analysis of the amino
acid sequence of SMPDL3b revealed the possible existence of a
phosphatase domain. We therefore investigated if SMPDL3b may
be involved in the conversion of synthetic C1P to ceramide.
While experiments in transfected HEK293 cells strongly sug-
gested that SMPDL3b may convert C1P into ceramide, utilization
of puriﬁed soluble recombinant human SMPDL3b did not con-
ﬁrm a direct enzymatic activity of SMPDL3b, consistent with the
fact that other GPI-anchored enzymes may have impaired activity
when lacking their GPI anchor23. These data, in conjunction with
our prior report that SMPDL3b overexpression is also associated
with increased sphingosine-1-phosphate (S1P) levels24, suggest
that SMPDL3b regulates the content of active sphingolipids, such
as S1P and C1P. In nephrology, S1P has been studied extensively
in the context of acute kidney injury25 and has recently generated
attention when a mutation of the gene encoding for S1P lyase,
resulting in accumulation of S1P, was found to be associated with
nephrotic syndrome9, similar to what was described in S1P lyase-
deﬁcient mice7. On the contrary, much less is known about C1P,
as its pro-inﬂammatory or anti-inﬂammatory role is still a matter
of debate6,26–28. C1P has been shown to modulate AKT phos-
phorylation in skin ﬁbroblasts, hematopoietic cells29, macro-
phages30, adipocytes31, consistent with the observation that
several sphingolipids are major modulators of insulin
signaling32,33. As ceramide has been shown to be a master reg-
ulator of insulin signaling and the primary antagonist of protein
kinase B (AKT) in culturing myotubes and liver34–36, the fact that
SMPDL3b affects overall C1P content without affecting ceramide
Fig. 3 SMPDL3b interacts with IRA, IRB, and caveolin-1 in a competitive manner. a–c Immunoprecipitation (IP) experiments performed in HEK293 cells co-
transfected with human hIRA-FLAG, hIRB-FLAG, hSMPDL3b-GFP, hSMPDL3b-HA hSMPDL3b-H135A-HA, hCav1-FLAG, and hCav1-GFP plasmids. Empty
FLAG vector (Empty-FLAG) was used as a negative control. Antibodies (IB) against FLAG, SMPDL3b, insulin receptor β-subunit (IR), or caveolin-1 (Cav1)
were used in Western blot analysis. Each IP experiment was repeated at least three times. a SMPDL3b interacts with both IR isoforms but preferentially
with IRA. bWildtype SMPDL3b interacts with IRA, IRB, and caveolin-1, a mutation (H135A) in the phosphodiesterase activity domain of SMPDL3b does not
affect these interactions. c Overexpression of SMPDL3b enhances the interaction between caveolin-1 and IRA (left panel) and suppresses the interaction
between caveolin-1 and IRB (right panel). d Endogenous IP experiments using glomeruli isolated from ﬁve C57BL/6 mice indicate that SMPDL3b
immunoprecipitates insulin receptor and caveolin-1. IgG served as a negative control. Each IP was repeated three times. e Western blot and bar graph
analysis of AKT and p70S6K phosphorylation in control (CTRL) and SMPDL3b overexpressing (SMP OE) podocytes pre-treated with 5mM methyl-
β-cyclodextrin (CD) and stimulated with 1 nM insulin; *P= 0.02, **P= 0.001, two-tailed t-test. n= 3 independent experiments. f IP experiments performed
in HEK293 cells co-transfected with human hIRA-FLAG, hIRB-FLAG, hCav1-GFP, and hSMPDL3b-HA show that 5 mM CD treatment abrogates IRA/Cav1
interaction and restores IRB/Cav1 interaction in presence of SMPDL3b overexpression. g Western blot and bar graph analysis of the insulin receptor (IR)
and SMPDL3b localization at the plasma membrane (PM) in CTRL and SMP OE podocytes exposed to 5mM CD for 1 h; *P= 0.049, ***P= 0.0001 (for IR);
$P= 0.024, #P= 0.031 (for SMPDL3b); two-tailed t-test. n= 3 independent experiments. Error bars represent standard deviation (SD)
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does not exclude the possibility that SMPDL3b inﬂuences the
ceramide/C1P ratios in PMs of podocytes, thus contributing to
insulin resistance. It is possible that the increased ceramide
generation in SMPDL3b overexpression cells still plays a key role
in the induction of insulin resistance and that our failure to detect
a change in ceramide content is linked to its rapid degradation
and/or conversion to other substrates. However, should ceramide
rather than C1P deﬁciency be the major driver of insulin resis-
tance in our model, then the administration of C1P in diabetes
would result in increased ceramide production and further
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worsening of DKD, and the observed improvement of AKT
phosphorylation in vitro and in vivo would remain unexplained.
The effect of SMPDL3b on insulin signaling, in association with
the observation that SMPDL3b is a lipid raft-associated enzyme4,
prompted us to test the hypothesis that SMPDL3b may interfere
with the PM localization and function of IR. We ﬁrst veriﬁed that
genes involved in the PI3K-AKT signaling pathway were affected
in cells overexpressing SMPDL3b. In SMP OE podocytes, the
ability of insulin to cause AKT phosphorylation was severely
impaired, while the ability to phosphorylate p70S6K was aug-
mented. These functional data suggested a differential regulation
of IR isoform signaling, as it was shown before that in pancreatic
beta cells where IRB signaling is primarily linked to AKT phos-
phorylation and dependent on its localization in lipid raft
domains for proper function13. Increased SMPDL3b expression
was not associated with a change in IR expression but affected IR
localization to PM. While it is not possible to discriminate if this
change in localization affects IRA or IRB, it seems feasible to
suggest that it primarily affects IRB, which is the predominantly
expressed isoform in podocytes. We therefore tested if SMPDL3b
interferes with the localization of the IR to the PM by interfering
with IR binding to caveolin-1. We utilized HEK293-transfected
cells and found that SMPDL3b can bind to either IRA or IRB or
caveolin-1. Endogenous SMPDL3b binding to IR and caveolin-1
was conﬁrmed by IP in glomeruli isolated from kidney cortexes.
Binding of SMPDL3b to caveolin-1 or to IR did not require its
phosphodiesterase function, suggesting the existence of an
enzymatic regulation of protein complex formation affecting
insulin signaling in lipid raft domains. Since the interaction
between IR and caveolin-1 has been proven to be essential for IR
signaling37–39, and accumulation of the ganglioside GM3 to
caveolae microdomains causes the dissociation of IR-caveolin-1
complexes and increased IR motility in adipocytes15, we deter-
mined if SMPDL3b interferes with the ability of IR to interact
with caveolin-1. Indeed, we demonstrated that SMPDL3b can
interfere with the binding of IRB to caveolin-1, while facilitating
IRA binding to caveolin-1, which may be responsible for
increased insulin-stimulated p70S6K phosphorylation. Treatment
with methyl-beta-cyclodextrin, which was found to act as a
chemical caveolin-1 inhibitor21, reduced SMPDL3b PM locali-
zation and was sufﬁcient to restore IR localization to PM and to
restore the ability of insulin to phosphorylate AKT. The ability of
sphingolipids to affect insulin signaling has been studied in sev-
eral organs. Sarcolemmal ceramides and sphingomyelins regulate
insulin sensitivity in human skeletal muscles40. In adipocytes, S1P
deﬁciency can lead to insulin resistance via decreased activity of
the peroxisome proliferator-activator receptor γ41 or via accu-
mulation of GM3, which has been shown to dissociate the IR beta
subunit from caveolin-115. Earlier studies also demonstrated that
high ceramide concentrations are associated with insulin resis-
tance in rodent liver, as well as in skeletal muscles from rats and
obese patients42,43. Summers et al. (2010) demonstrated that
ceramide blocks insulin stimulation of AKT by two independent
pathways: by blocking AKT translocation to the PM and by
dephosphorylation of AKT by protein phosphatase 2A44. To our
knowledge, however, this is the ﬁrst report of how sphingolipids
may differentially affect IR isoform signaling by the displacing
IRB isoform from caveolin-1 rich domains of the PM.
In order to understand the in vivo relevance of SMPDL3b in the
context of diabetic complications that are linked to impaired
insulin signaling such as DKD, we generated podocyte-speciﬁc
Smpdl3b-deﬁcient mice. These mice are phenotypically normal,
similar to what we described for SMPDL3b-deﬁcient podocytes2.
Generation of db/db mice with a podocyte-speciﬁc deletion of
Smpdl3b resulted in a protection from developing DKD, with
reduced albuminuria and mesangial expansion and preservation of
podocyte numbers. This occurred in association with the restora-
tion of the C1P content in kidney cortexes, and restoration of
podocyte-speciﬁc AKT phosphorylation. C1P treatment was not
associated with renal or liver toxicity or with changes in the con-
centration of circulating lipids. In order to understand if the
protection observed in Smpdl3b-deﬁcient mice was linked to the
decreased C1P content, we performed additional in vitro and
in vivo experiments with exogenous supplementation of C1P.
Similar to what was observed in skin ﬁbroblasts30, exogenous C1P
administration was associated with increased AKT phosphoryla-
tion in vitro and with protection from albuminuria and mesangial
expansion in db/db mice in vivo. These ﬁndings open the door for
the use of active lipids as potential new therapeutic agents in the
ﬁeld of diabetes and associated complications. In fact, modulation
of enzymes involved in sphingolipid metabolism, such as acid
and neutral ceramidases has been studied as a therapeutic option
in Alzheimer’s disease45,46, cancer research47,48, and diabetes41,46.
Interestingly, and similar to what we have observed, an imbalance
in C1P and S1P availability is also critical in the progression of
other diseases, such as glioblastoma49, acute lung injury50,51,
Parkinson’s disease52, pancreatic cancer cells53, and
chronic inﬂammatory processes54,55. Nevertheless, little is known
about the potential utilization of C1P and S1P analogs as ther-
apeutic agents.
In conclusion, we demonstrated a mechanism by which
sphingolipids may affect PM signaling (Fig. 6h). We have utilized
IR to demonstrate how active lipid products of SMPDL3b may
interfere with IR signaling in lipid raft domains and how
administration of deﬁcient lipid species may restore IR signaling
and protect from DKD. Our study has limitations, as the tech-
nical inability to differentiate endogenous IRA and IRB signaling
or to determine the enzymatic activity of recombinant non-GPI-
Fig. 5 Podocyte-speciﬁc Smpdl3b-deﬁcient diabetic mice are protected from DKD. Four groups of 28 weeks-old mice were utilized: (1) wildtype mice (+/+;
+/+), n= 10 animals; (2) mice with podocyte-speciﬁc Smpdl3b deﬁciency (ﬂ/ﬂ;+/+), n= 11 animals; (3) diabetic mice (+/+;db/db), n= 9 animals; (4)
podocyte-speciﬁc Smpdl3b-deﬁcient diabetic mice (ﬂ/ﬂ;db/db), n= 9 animals. a A graph showing body weight changes in all four groups of mice during the
study. b A bar graph showing kidney to body weight (KW/BW) ratio in all four groups of mice at sacriﬁce time point. ***P < 0.0001, F= 44.79, one-way
ANOVA. c A bar graph showing urine albumin to creatinine ratio (ACR) in all four groups of mice at sacriﬁce time point. ****p < 0.0001, F= 42.24, one-
way ANOVA. d PAS staining (40×) of 4 μm kidney sections and bar graph analysis in all four groups of mice. Bar scale 30 µm. ****P < 0.001, F= 47.17,
one-way ANOVA. e–g LC–MS analysis of total ceramide (e), total sphingomyelin (f) and total ceramide-1-phosphate (g) content in kidney cortexes of all
four groups of mice. P= 0.317, F= 1.38 (total ceramide), P= 0.764, F= 0.388 (total sphingomyelin), one-way ANOVA; *P= 0.023, **P= 0.002 (total
ceramide-1-phosphate), two-tailed t-test. n= 3 animals per group. h Representative immunostaining (40×) for anti-Wilms’ Tumor 1 (WT1, green) and
DAPI (blue) in 4 µm kidney sections of all four groups of mice. Bar scale 30 µm. *P= 0.016, **P= 0.037, two-tailed t-test. n= 3 animals per group.
i Representative TEM and bar graph analysis of foot process effacement (yellow arrow) and glomerular basement membrane (GBM) thickness (yellow
asterisk) in +/+;db/db and ﬂ/ﬂ;db/db mice. Bar scale 500 nm. *P= 0.020, **P= 0.001, two-tailed t-test. n= 3 animals per group, n= 10 micrographs
analyzed per mouse. j Representative immunostaining (40×) for pAKT (Ser473) (green) and synaptopodin (red; SYNPO) in 4 µm kidney sections and bar
graph analysis demonstrating increased AKT phosphorylation in all four groups of mice. Bar scale 30 µm. **P= 0.001, ****P < 0.0001, F= 37.48, one-way
ANOVA. n= 3 animals per group. Error bars represent standard deviation (SD)
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anchored SMPDL3b. In addition, while our studies have been
limited to the kidney, understanding the function of SMPDL3b in
other organs and in other disease processes may lead to additional
therapeutic potential. As pharmacological suppression of
SMPDL3b may render cells susceptible to other forms of injury
and an activation of innate immunity pathways2–4, the alternative
approach to utilize C1P replacement strategies may result in a
safer and more effective strategy to treat DKD. Further studies
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investigating C1P administration in vivo will open the door to
therapies with bioactive lipids targeting the most prevalent form
of kidney disease worldwide.
Methods
Reagents, antibodies, dilution, and mice. RPMI 1640 media for podocytes cul-
ture was obtained from Corning (NY, USA; #10-040-CV). DMEM media with 4.5
g/l glucose, L-glutamine and sodium bicarbonate (#11995-073) for HEK293 cell
culture was obtained from ThermoFisher Scientiﬁc Inc. (CA, USA). Dynabeads M-
270 Epoxy Co-IP Kit (#14321D) was obtained from ThermoFisher Scientiﬁc Inc.
Human insulin (#I9278-5ML), CD (#H107-100G), 4-nitrophenol standards
(#1048-5G) and bis-p-nitrophenolphosphate (#N3002) for phosphodiesterase assay
were obtained from Sigma-Aldrich (MO, USA). C16:0 C1P (#860533) and C6-
NBD-Ceramide (#810209P) were obtained from Avanti Polar Lipid (AL, USA).
Recombinant human SMPDL3b protein, MYC/DDK-tagged was ordered from
Creative Biomart (#SMPDL3b-2823H).
Anti-caveolin-1 (#3251 for phospho-Cav1(Tyr14), dilution 1:1000, #3267 for
Cav1 (D46G3) XPTM, dilution 1:1000), anti-IR β subunit (4B8) (#3025, dilution
1:100), anti-Na/K-ATPase (#3010, dilution 1:1000), anti-MEK-1/2 (D1A5) (#8727,
dilution 1:1,000), anti-AKT (#9271 for phospho-AKT (Ser473) (D9E), dilution
1:1000, #9272 for tAKT, dilution 1:1000), anti-p70S6Ke (#9234 for phosphor-
p70S6K (Thr389 (108D2)), dilution 1:1000, #9202 for p70S6K, dilution 1:1000),
anti-4EBP1 (#2855 for phospho-4E-BP1 (Thr37/46) (236B4), dilution 1:1000,
#9644 for 4E-BP1, dilution 1:1000) primary antibodies were purchased from Cell
Signaling Technology (MA, USA). SMPDL3b antibodies purchased from GenWay
Biotech (CA, USA, #GWB-2281D4, dilution 1:1000). IR β subunit antibodies (CT-
1) for endogenous IP (#MA5-13778, dilution 1:250) were obtained from
ThermoFisher Scientiﬁc Inc., HRP-conjugated secondary antibodies from Promega
Corp. (WI, USA) and used in dilution 1:10,000, anti-rabbit TrueBlot HRP-
conjugated secondary antibodies from Rockland (PA, USA, #18-8816-31, dilution
1:2,000). For immunoﬂuorescence primary rabbit polyclonal anti-WT1 (WT1; #sc-
192, dilution 1:300) and anti-goat polyclonal synaptopodin (P19; #sc-21537,
dilution 1:500) antibodies were purchased from Santa Cruz Biotechnology (TX,
USA), rabbit polyclonal SMPDL3b antibodies from GenWay (#GWB-2281D4,
dilution 1:200) and rabbit monoclonal pAKT (Ser473; #9271, dilution 1:300)
antibodies from Cell Signaling Technology. Alexa ﬂuorescence 568 (red; #A10042;
#11061, dilution 1:500), 488 (green; # A11059, dilution 1:500) secondary antibodies
and DAPI (#D1306) were obtained from Invitrogen | Thermo Fisher Scientiﬁc
(CA, USA). For ﬂow cytometry, human BD Fc Block reagent (#564220) was
obtained from BD Bioscience, Human/Mouse Insulin R/CD220 APC-conjugated
antibodies (#FAB1544A, dilution 1:10) and isotope control IgG APC-conjugated
antibodies (#IC108A, dilution 1:30) were obtained from R&D Systems.
Mice in which exon 2 of Smpdl3b is ﬂanked by loxP sites were purchased from
the International Knockout Mouse Consortium (B6N;B6N-SMPDL3btm1a
(EUCOMM)Wtsi/H; #MGI:1916022). Mice carrying a Flp-recombinase transgene
(B6.129S4-Gt(ROSA)26Sortm1(FLP1)Dym/RainJ; #009086), mice carrying a Cre-
recombinase transgene speciﬁcally expressed in podocytes (B6.Cg-Tg(NPHS2-cre)
295Lbh/J; catalog #008205) and Leprdb heterozygous db/+ and homozygous db/db
mice (B6.BKS(D)-Lepr<db>/J; catalog #000697) were purchased from the Jackson
Laboratories (USA). 18% protein rodent chow diet was ordered from Tekland
Global (Envigo, WI, USA; #2018S).
Plasmids. A full-length human SMPDL3b with GFP tag (hSMPDL3b-pCMV6-AC-
GFP; #RG217688), human caveolin-1 with GFP tag (hCav1-pCMV6-AC-GFP;
#RG210274), human caveolin-1 with FLAG tag (hCav1-pCMV6-Myc-DDK;
#RC210274), and pCMV6-AC-3DDK empty vector (#PS100057) were ordered from
OriGene (MD, USA). A full-length human IR isoform A with FLAG tag (hIRA-
FLAG-pRC/CMV) and a full-length human IR B with FLAG tag (hIRB-FLAG-pRC/
CMV) plasmids were a kind gift from our collaborator Dr. Ingo Leibiger13. A full-
length human HA-tagged SMPDL3b plasmid (pTO-SP-HA-hSMPDL3b) and HA-
tagged SMPDL3b plasmid with mutation in 135 histidine (pTO-SP-HA-hSMPDL3b-
H135A) were a kind gift from our collaborator Dr. Leonhard Heinz4.
Cell culture. A human podocyte cell lines transfected with a thermosensitive SV40-
T construct were cultured on type I collagen-coated ﬂasks in RPMI media sup-
plemented with 10% FBS, 1% penicillin/streptomycin, and 1% ITS at 33 °C to
promote cells proliferation56. Before thermoswitching to 37 °C to promote cells
differentiation, cells were grown to conﬂuence 70–80% and trypsinized and
reseeded in fresh ﬂasks at a dilution 200,000 cells per 10 ml of RPMI media without
ITS. The origin of normal human podocytes (control) is a kind gift of Dr. Jochen
Reiser, Rush University, Chicago. SMPDL3b overexpression human podocytes
were developed by Dr. Fornoni and validated in ref. 2.
HEK293 cells were obtained from ATCC (Manassas, VA; #CRL-1573TM).
HEK293 cells were cultured in DMEM media supplemented with 10% FBS and 1%
penicillin/streptomycin at 37 °C. Prior to transfection procedure, cells were grown
to conﬂuence 70–80%.
Treatment of human podocytes. For treatments, human podocytes were differ-
entiated for 14 days and serum starved for 24 h starting day 13. Stimulation with
human insulin was performed at concentrations of 0.1 and 1 nM for 30 min at 37 °
C. For kinetics of the insulin signaling over time, podocytes were treated with 1 nM
of insulin for 0, 2, 5, 10, 15, 20, 25, and 30 min. Treatment with CD was performed
at a concentration of 5 mM for 1 h at 37 °C. C1P was used for treatment at a
concentration of 100 μm for 1 h at 37 °C. C1P stock solution (ﬁnal concentration
1.47 mM) was prepared by sonication of C1P in sterile nanopure water on ice using
a probe sonicator, until a clear dispersion was obtained57. Untreated wildtype
podocytes served as a control.
LC–MS analysis. Cell lysates from differentiated control (CTRL) and SMP OE
podocytes or kidney cortexes from mice were used for lipidomics analysis. LC–MS
analysis was performed in Medical University of South Carolina, Lipidomics shared
resource (SC, USA). Cells pellets containing at least 1 × 106 cells per sample in vitro
or at least 25 mg of kidney cortex per sample in vivo were subjected to liquid
extraction58.
Phosphodiesterase enzymatic activity assay. Enzymatic activity in CTRL and
SMP OE podocytes was measured according to a previously published protocol4.
Brieﬂy, CTRL and SMP OE podocytes were differentiated for 14 days at 37 °C in
96-well plates and starved for 24 h. To measure the phosphodiesterase activity,
podocytes were incubated with isotonic Tris-buffered saline in the presence of 1
mM substrate at 37 °C and 5% CO2 for 1 h. Phosphodiesterase activity in WT and
SMP OE podocytes was measured by generation of p-nitrophenol from bis-p-
nitrophenolphosphate as absorbance at 405 nm in 100 μl reaction volume.
C1P phosphatase assay. C1P phosphatase was assayed in vitro using homo-
genates from HEK293 cells transfected with hSMPDL3b-pCMV6-Myc-DDK or
pCMV6-AC-3DDK essentially as described59. Brieﬂy, 50 μM C6-NBD-C1P com-
plexed to 10 μM BSA was incubated with homogenates (2 μg of protein) in 200 mM
NaCl, 2 mM EDTA, 100 mM HEPES, pH 7.4 and a protease inhibitor cocktail
(1:200) for 10 min at 37 °C. The reaction was terminated by addition of 3.75
volumes of chloroform:methanol (1:2), 1.25 volume of chloroform and 1.25
volumes of 2M KCl/0.2 M H3PO4. The lower phase was dried under N2 and lipids
subsequently resolved by TLC on Silica Gel plates using chloroform:methanol:
Fig. 6 Exogenous C1P replacement restores the ability of SMPDL3b overexpressing podocytes to phosphorylate AKT and reduces albuminuria in diabetic
mice. a, b Western blot and bar graph analysis of phosphorylated AKT (pAKT) to total AKT (tAKT) (a) and phosphorylated p70S6 kinase (p-p70S6K) to
total p70S6 kinase (t-p70S6K) (b) in control (CTRL) and SMPDL3b overexpressing (SMP OE) human podocytes pre-treated with synthetic C1P (100 µM)
and treated with insulin (1 nM); *P < 0.05, **P < 0.001, ***P < 0.0001, F= 9.66 (for AKT), F= 3.94 (for p70S6K), one-way ANOVA. n= 3 independent
experiments. c LC–MS analysis of ceramide species in kidney cortexes of control mice (db/+) and diabetic mice (db/db). ****P < 0.0001, F= 27.18, two-
way ANOVA. n= 3 animals per group. d For exogenous C1P administration in vivo three groups of 12-week-old mice were utilized: (1) control heterozygous
mice intraperitoneally (I.P.) injected with 0.9% normal saline (db/+NS), (2) diabetic mice I.P. injected with 0.9% normal saline (db/db NS), 3) diabetic
mice I.P. injected with 30mg/kg C1P for 28 days (db/db C1P). n= 6 animals per group. A bar graph showing albumin–creatinine ratio (ACR) in db/+NS,
db/db NS and db/db C1P mice. **P= 0.002, F= 10.1, one-way ANOVA. e Representative PAS staining (20×) in 4 μm kidney sections and bar graph
analysis in db/+NS, db/db NS, and db/db C1P mice. Bar scale 20 µm. *P= 0.043, **P= 0.002, F= 9.47, one-way ANOVA. f Representative
immunostaining (40×) for pAKT (Ser473) (green) and synaptopodin (red; SYNPO) in 4 µm kidney sections and bar graph analysis in db/+NS, db/db NS,
and db/db C1P mice. Bar scale 30 µm. *P= 0.044, ****P= 0.0001, F= 8.03, one-way ANOVA. g Bar graph analysis of fasting glycemia (left panel)
and area under curve of glucose tolerance test (right panel) after intraperitoneal injection of 1.5 g/kg D-glucose in db/+NS, db/db NS, and db/db C1P mice.
*P= 0.013, **P= 0.008, ***P < 0.0001, F= 9.86 (for fasting glycemia), F= 67.31 (for AUC of IPGTT), one-way ANOVA. Error bars represent standard
deviation (SD). h Proposed mechanism by which increased SMPDL3b expression contributes to the pathogenesis of DKD and possible targeting strategies
to prevent DKD development. (↑) overexpression, (↓) suppression, CD - cyclodextrin, exC1P - exogenous C1P
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acetic acid: 15 mM CaCl2 (60:35:2:4, v/v/v/v) as developing solvent. For experi-
ments with puriﬁed SMPDL3b, 50 μM C6-NBD-C1P complexed to 10 μM BSA was
incubated with SMPDL3b in concentrations 0, 100, 500, and 1000 ng following the
steps described above.
Illumina sequencing RNA data analysis. Preparation and sequencing of RNA
libraries was carried out in the John P. Hussman Institute for Human Genomics
Center for Genome Technology. Brieﬂy, total RNA was quantiﬁed and qualiﬁed
using the Agilent Bioanalyzer to have an RNA integrity score (RIN) above 7. For
each of the six samples, 500 ng of total RNA was used as input for the Illumina
TruSeq Stranded Total RNA Library Prep Kit with Ribo-Zero to create ribosomal
RNA-depleted sequencing libraries. Each sample had a unique barcode to allow for
multiplexing and >35 million raw reads in a 2 × 100 paired end sequencing run on
the Illumina HiSeq3000 were obtained.
Raw sequence data were processed by the on-instrument Real Time Analysis
software (v.2.7.7) to basecall ﬁles. These were converted to de-multiplexed FASTQ
ﬁles with the Illumina supplied scripts in the BCL2FASTQ software (v2.17). The
quality of the reads was determined with FASTQC software for per base sequence
quality, duplication rates, and overrepresented k-mers. Illumina adapters were
trimmed from the ends of the reads using Trim Galore! package. Reads were
aligned to the human reference genome (hg19) with the STAR aligner (v2.5.0a)60.
Gene count quantiﬁcation for total RNA was performed using the GeneCounts
function within STAR against the GENCODE v19 transcript ﬁle.
Gene count data were input into edgeR software61 for differential expression
analysis. Brieﬂy, gene counts were normalized against total aligned reads for each
sample to generate counts per million (cpm) expression value for each gene in each
sample. Given the relatively small sample size per group for comparison (n= 3 in
each group) the exact test implemented in edgeR was used to determine differential
expression including a false discovery rate P-value.
To discover enriched functional-related gene groups, DAVID bioinformatics
resource 6.8 was used.
Isolation of PMs. Cells were collected in homogenization media (15 mM KCl, 1.5
mM MgCl2, 10 mM HEPES, 1 mM DTT) and incubated on ice for 5 min. Cell
pellets were homogenized ﬁve times using insulin syringes and incubated with 2.5
M sucrose solution (250 nM ﬁnal concentration). Cell pellets were submitted to
several centrifugation steps: to separate nuclear fraction (1000 × g, 5 min, 4 °C); to
separate mitochondrial and endoplasmic reticulum fraction (10,000 × g, 15 min, 4 °
C); to separate PM fraction and cytosolic fraction (100,000 × g, 1 h, 8 °C). Resulting
membrane pellets were collected and resuspended in 50 μl of homogenization
media followed by Western blot analysis. Cytosolic fractions were concentrated in
3–4 times using 3K concentrators, 20,000 × g, 30 min, 4 °C followed by Western
blot analysis. Na/K-ATPase was used as a marker of PM fraction, and MEK-1/2
was used as a marker of the cytosolic fraction.
Flow cytometry. CTRL or SMP OE human podocytes were collected at day 14 of
differentiation and incubated with 0.5% BSA, 0.1% Saponin in 1 × PBS for 10 min
at room temperature followed by Fc blocking step for 10 min at room temperature
using 12.5 µg of human BD Fc Block solution. Incubation with 30 µl of IR APC-
conjugated antibodies per sample was performed for 1 h at room temperature in
dark. HEK293 IR-transfected cells were served as positive control. CTRL human
podocytes incubated with 10 µl of isotop control IgG APC-conjugated antibodies
were used as a negative control. Fluid sheath running through the cytometer was
highly ﬁltered (0.22 μm ﬁlters). FACS experiments were performed in four biolo-
gical replicates and 30,000 events per sample were analyzed. Fluorescence exclusion
was used to gate on live cells. Intact cells were identiﬁed by conventional ﬂow
cytometry using side scatter area (SSC-A) and forward scatter area (FSC-A). IR-
positive cells were determined using negative and positive controls gating (Sup-
plementary Fig. 6). Results were read on BD LSR II 15-color ﬂow cytometric
analyzer using PE ﬂuorochrome with laser lens 535 nm and emission ﬁlters 585/15.
All data were analyzed using FACSDiva 8.0.2 software.
PCR analysis to differentiate IR isoforms. mRNA from human podocytes was
extracted using RNAeasy kit according to the manufacture’s protocol. 250 ng RNA
was reverse transcribed to obtain cDNA using the high-capacity cDNA reverse
transcriptase kit according to the manufacturer’s protocol. PCR was performed
using GoTaq green master mix at 58 °C, 35 cycles yielding a 222-bp PCR products
corresponding to IR isoform B and a 186-bp PCR product corresponding to IR
isoform A, using primer sequences reported in Supplementary Table 117.
Transient transfection and IP. HEK293 cells were grown until 70–80% con-
ﬂuence prior any transfection. Transient transfection was performed using
FuGene-6 reagent, OPTI-MEM media, and 1 μg of plasmid and incubated in
antibiotic-free DMEM media for 24 h. Then cells were grown in DMEM media
supplemented with 10% FBS and 1% penicillin/streptomycin for next 24 h and
starved for 2–4 h in DMEM with 0.1% FBS and 1% penicillin/streptomycin prior
treatment or cells collection. Cell pellets were collected in Triton buffer (50 mM
Tris, pH 7.5, 150 mM NaCl, 1% Triton) and were precipitated with anti-FLAG M2
Afﬁnity Gel62. After a wash pellets were analyzed by standard SDS gel
electrophoresis. Endogenous Co-IP was performed on isolated glomeruli from
wild-type B6N mice using Dynabeads M-270 Epoxy Co-IP Kit according to
manufacturer’s protocol. Brieﬂy, Dynabeads were coupled with IR antibodies.
Proteins from isolated glomeruli were obtained using extraction buffer (100 mM
NaCl, 2 mM MgCl2, 1 mM DTT, 1:200 protease inhibitor without EDTA).
Antibody-coupled beads were incubated with lysates (1.5 mg of antibody-coupled
beads per 1.5 g of isolated glomeruli) at 4 °C for 30 min, followed by washing steps
with buffers (5 min in 200 μl 1 × LWB and 5 min in 60 μl 1xEB) provided by the kit.
Animal studies. All animal studies have complied with all relevant ethical reg-
ulations and were performed in accordance with the National Institutes of Health
Guidelines. The study protocol was approved by the Institutional Animal Care and
Use Committee of the University of Miami, Miller School of Medicine.
Genotyping, housing, and phenotypic analysis of mice. To generate podocyte-
speciﬁc Smpdl3b-deﬁcient mice, Cre-loxP technology was used. Mice with a
Smpdl3b-targeted allele were crossed to Flp-recombinase carrying mice63 to gen-
erate heterozygous Smpdl3b ﬂoxed mice with a deleted FRT-Neo cassette (Fig. 4a,
Supplementary Fig. 3). These were then mated with Podocin-Cre Tg/Tg mice22 to
generate heterozygous Podocin-Cre positive Smpdl3b ﬂoxed mice (Cre+;ﬂ/+).
Finally, the latter were intercrossed to generate homozygous podocyte-speciﬁc
Smpdl3b-deﬁcient mice (Cre+;ﬂ/ﬂ). As Podocin-Cre and Flp-recombinase trans-
genic mice were used in a pure C57BL/6 background and ﬂoxed Smpdl3bmice were
used in a C57BL/6N background, wildtype littermates were used as a control to
account for phenotypical variability due to background differences.
For genotyping, tissues from tail biopsies of 3-week-old mice were digested with
proteinase K and DNA was isolated using QIAamp DNA Mini kit according to the
manufacture’s protocol. Smpdl3b, Flp- and Cre- recombinase alleles were detected
using PCR (information on primers used for genotyping is available in
Supplementary Table 4). Podocin-Cre transgenic mice22 were identiﬁed using
primers speciﬁc for this transgene, yielding a 455 bp PCR product (Supplementary
Fig. 3a). To distinguish wildtype mice from podocyte-speciﬁc Smpdl3b-deﬁcient
mice, which are characterized by the presence of a 3′-loxP site downstream of exon
2 of the Smpdl3b gene, a genotyping PCR on tail biopsies was established. In this
PCR, a set of four primers to detect the wildtype (WT1 and WT2) and the ﬂoxed
allele (KO1 and KO2) giving rise to a 315 bp and 237 bp PCR product, respectively,
was used (Supplementary Fig. 3a). To ensure successful Cre-mediated
recombination, which is only detectable in podocytes, PCR on genomic DNA
isolated from glomeruli using the primers 5FRT Fw, Smp_Del Rev and
FRT_Del_Fw (Supplementary Table 1) was also performed. This PCR will only
yield a 198 bp product if Cre-mediated recombination has occurred
(Supplementary Fig. 3b). A 1075 bp band can be detected in all other cells of a
glomerulus.
Starting at 4 weeks of age, weight measurements and morning spot urines were
collected bi-weekly until mice reached 28 weeks of age. Male and female mice were
analyzed in all study groups. Six to ten mice per group (Cre+;+/+– wildtype mice
(n= 10) and Cre+/ﬂ/ﬂ –podocyte-speciﬁc Smpdl3b knockout mice (n= 6)) were
sacriﬁced and in-depth phenotypical analysis was performed, including urinary
albumin-to-creatinine ratio, histological analysis (PAS, H&E), glomeruli isolation
and blood analysis.
Heterozygous Podocin-Cre positive Smpdl3b-ﬂoxed mice (Cre+;ﬂ/+) were
crossed to Leprdb heterozygous db/+ mice to generate double heterozygous mice
(Cre+;ﬂ/+;db/+). The latter were intercrossed to generate double mutant mice
(Cre+;ﬂ/ﬂ;db/db).
For genotyping, tissues from tail biopsies was digested as described above. Smpdl3b,
db, and Cre- recombinase alleles were characterized using PCR (information on
primers used for genotyping is available in Supplementary Table 4).
Starting at 4 weeks of age, weight and glycemia level measurements and
morning spot urines were collected bi-weekly until mice reached 28 weeks of age.
Ten mice per group were sacriﬁced and in-depth phenotypical analysis was
performed, including urinary albumin-to-creatinine ratio, histological analysis
(PAS, H&E, PSR), transmission electron microscopy analysis (GBM thickness and
foot process effacement quantiﬁcation), immunohistochemistry, glomeruli
isolation, and serum analysis.
All mice were housed in MicroVENT IVC standard ventilated cages (Allentown
Inc., PA, USA) maintained at 68 ± 4°F with 12 h dark and 12 h light cycle and
provided water and Tekland Global 18% protein rodent chow diet with no restrictions.
Urine samples analysis. Morning urine spot was collected bi-weekly. The urine
albumin content was measured by ELISA and urinary creatinine was measured by
an assay based on the Jaffe method, using albumin ELISA kit from Bethyl Lab.
(#E90-134; TX, USA) and creatinine kit from Stanbio (#0420-500; TX, USA).
Values are expressed as microgram albumin per milligram creatinine.
Histology and assessment of mesangial expansion. After perfusion of an animal
with 1 × PBS, the right kidney was removed for histological analysis and the left
kidney was collected for glomeruli extraction. Periodic acid-Schiff (PAS) and
hematoxylin–eosin (H&E) staining of parafﬁn-embedded kidney sections (4 μm
thick) was performed using a standard protocol. Histological images were
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visualized using a light microscope (Olympus BX 41, Tokyo, Japan) at ×40 mag-
niﬁcation and analyzed using Image J software64. Twenty glomeruli per section
were analyzed for mesangial expansion by semi-quantitative analysis (scale 0–4)
performed by two blinded independent investigators65,66.
Transmission electron microscopy (TEM). For TEM, a kidney pole was ﬁxed in
2% paraformaldehyde (PFA), 2% glutaraldehyde in 0.1 M phosphate buffer (pH=
7.4) for at least one week prior to embedding. TEM was performed as described
previously67 with minor modiﬁcations. Samples were examined with a JEM-1011
transmission electron microscope (JEOL) in the University of Tokyo. Negatives of
electron micrographs at ×10,000 magniﬁcation were scanned at 600 d.p.i. Mea-
surements of the resulting images was performed using Image J software. Eight
images per mouse were analyzed using the distance between two points on a ruler
of a photograph as a measurement scale. GBM thickness was measured in 30
different points. The number of podocyte foot processes (FP) along the GBM was
counted by hand. A FP was deﬁned as any connected epithelial segment butting on
the basement membrane, between two neighboring ﬁltration pores or slits. From
each photograph, the arithmetic mean of the foot process width (FPW) was cal-
culated as follows: FPW= π/4*ΣGBM length/Σfoot process68.
Blood samples analysis. Blood samples were analyzed for lipid panel, aspartate
aminotransferase (AST), alanine transaminase (ALT), and blood urea nitrogen (BUN)
in the Comparative Laboratory Core Facility of the University of Miami. Serum
creatinine was determined by tandem mass spectrometry at the UAB-UCSD O’Brein
Core Center (University of Alabama, Birmingham) as previously described69.
Immunoﬂuorescence staining and confocal microscopy. For immuno-
ﬂuorescence staining of kidneys from mice, fresh cut 4 μm-thick tissue in OCT was
used. No ﬁxation agent was applied. Permeabilization was performed using 0.3%
Triton X-100 in 1 × PBS for 10 min at room temperature. A blocking step was
performed using 5% BSA, 2.5% FBS in PBS for 1 h at room temperature. Primary
antibodies were used for 24 h at room temperature. Alexa-conjugated secondary
antibodies were used for 1 h at room temperature. To detect nucleus, DAPI
staining was applied in a 1:500 dilution for 20 min at room temperature.
To assess podocyte number and apoptosis in murine glomeruli,
immunoﬂuorescent labeling with anti-WT1 was performed. WT1-positive nuclei were
counted in 20 consecutive glomerular cross-sections per animal by two blinded
investigators11.
Images were acquired by laser scanning confocal microscopy using a Leica SP5
Inverted microscope, ×40 wet objective (Leica Microsystems CMS GmbH,
Germany). Measuring of cell ﬂuorescence was performed using Image J software70.
Exogenous C1P treatment of diabetic mice. Six 12-week-old homozygous db/db or
heterozygous db/+ mice received daily intraperitoneal injections of 30mg/kg C1P
C16:0 or 0.9% normal saline (NS) for 28 days. To prepare a stock solution (5 mg/ml),
C1P C16:0 powder was weighted and dissolved in 0.9% NS and 2.5% DMSO by
sonication. Aliquots were stored at −20 °C, then melted and sonicated once again
before application. Urine collection, body weight, and glycemia measurements were
determined weekly. Mice were sacriﬁced and in-depth phenotypical analysis was
performed, including urinary albumin-to-creatinine ratio, histological analysis (PAS,
H&E, PSR), glomeruli isolation and blood analysis as described previously. aspartate
aminotransferase (IPGTT) was performed 3 weeks after exogenous C1P adminis-
tration. After 12 h fasting, blood glucose was measured at baseline, and then at 15, 30,
60, 90, and 120min after a glucose bolus (1.5 g/kg).
Statistical analysis and study design. Data are expressed as a mean ± standard
deviation (SD). A number of experiments ranging between 3 and 5 was utilized as
indicated for each distinct experiment. Minimal group sizes for in vitro and in vivo
studies were determined via power calculator using the DSS Researcher’s Toolkit with
an α of 0.05. Animals were grouped unblinded, but randomized, and investigators
were blinded for the quantiﬁcation experiments. GraphPad Prism Outlier calculator
software was used to indicate outliers in each set of data obtained for in vitro and
in vivo experiments. Signiﬁcant outliers were excluded from further statistical analysis.
Two groups of data were compared using the two-tailed t-test. Three and more
groups of data were compared using the one-way analysis of variance (ANOVA),
followed by Tukey’s post-test or two-ways ANOVA with multiple comparisons. P <
0.05 was taken to indicate statistical signiﬁcance. Statistical analysis was performed
using the GraphPad Prism, version 7.0 (GraphPad Software Inc.).
Uncropped Western blots are depicted in Supplementary Figs. 7–10.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The raw data of lipidomic analysis in human podocytes and kidney cortexes of podocyte-
speciﬁc Smpdl3b deﬁcient mice and type 2 diabetic podocyte-speciﬁc Smpdl3b deﬁcient
mice are available in the Supplementary Datas 1, 3 and 5, respectively. All sequencing
data supporting the ﬁndings of this study are available in the Supplementary Datas 2 and
4 and have been deposited in the National Center for Biotechnology Information Gene
Expression Omnibus (GEO) and are accessible through the GEO Series accession
number GSE129666. Next publically available sources were used in the study: SMPDL3b
predicted domains (“SMPDL3b”). All other relevant data are available from the
corresponding author upon reasonable request.
Received: 20 June 2018 Accepted: 15 May 2019
References
1. Hannun, Y. A. & Obeid, L. M. Principles of bioactive lipid signalling: lessons
from sphingolipids. Nat. Rev. Mol. Cell Biol. 9, 139–150 (2008).
2. Fornoni, A. et al. Rituximab targets podocytes in recurrent focal segmental
glomerulosclerosis. Sci. Transl. Med. 3, 85ra46 (2011).
3. Yoo, T. H. et al. Sphingomyelinase-like phosphodiesterase 3b expression levels
determine podocyte injury phenotypes in glomerular disease. J. Am. Soc.
Nephrol. 26, 133–147 (2015).
4. Heinz, L. X. et al. The lipid-modifying enzyme SMPDL3B negatively regulates
innate immunity. Cell Rep. 11, 1919–1928 (2015).
5. Gorelik, A., Heinz, L. X., Illes, K., Superti-Furga, G. & Nagar, B. Crystal
structure of the acid sphingomyelinase-like phosphodiesterase SMPDL3B
provides insights into determinants of substrate speciﬁcity. J. Biol. Chem. 291,
24054–24064 (2016).
6. Chalfant, C. E. & Spiegel, S. Sphingosine 1-phosphate and ceramide 1-
phosphate: expanding roles in cell signaling. J. Cell Sci. 118, 4605–4612 (2005).
7. Janecke, A. R. et al. Deﬁciency of the sphingosine-1-phosphate lyase SGPL1 is
associated with congenital nephrotic syndrome and congenital adrenal
calciﬁcations. Hum. Mutat. 38, 365–372 (2017).
8. Lovric, S. et al. Mutations in sphingosine-1-phosphate lyase cause nephrosis
with ichthyosis and adrenal insufﬁciency. J. Clin. Investig. 127, 912–928
(2017).
9. Prasad, R. et al. Sphingosine-1-phosphate lyase mutations cause primary
adrenal insufﬁciency and steroid-resistant nephrotic syndrome. J. Clin.
Investig. 127, 942–953 (2017).
10. Tejada, T. et al. Failure to phosphorylate AKT in podocytes from mice with
early diabetic nephropathy promotes cell death. Kidney Int. 73, 1385–1393
(2008).
11. Guzman, J. et al. Podocyte-speciﬁc GLUT4-deﬁcient mice have fewer and
larger podocytes and are protected from diabetic nephropathy. Diabetes 63,
701–714 (2014).
12. Mima, A. et al. Glomerular-speciﬁc protein kinase C-beta-induced insulin
receptor substrate-1 dysfunction and insulin resistance in rat models of
diabetes and obesity. Kidney Int. 79, 883–896 (2011).
13. Leibiger, B. et al. Selective insulin signaling through A and B insulin receptors
regulates transcription of insulin and glucokinase genes in pancreatic beta
cells. Mol. Cell 7, 559–570 (2001).
14. Otsu, K. et al. Caveolin gene transfer improves glucose metabolism in diabetic
mice. Am. J. Physiol. Cell Physiol. 298, C450–C456 (2010).
15. Kabayama, K. et al. Dissociation of the insulin receptor and caveolin-1
complex by ganglioside GM3 in the state of insulin resistance. Proc. Natl Acad.
Sci. USA 104, 13678–13683 (2007).
16. Eduardsen, K. et al. Cell volume regulation and signaling in 3T3-L1 pre-
adipocytes and adipocytes: on the possible roles of caveolae, insulin receptors,
FAK and ERK1/2. Cell. Physiol. Biochem. 28, 1231–1246 (2011).
17. Villarreal, R. et al. Nephrin contributes to insulin secretion and affects
mammalian target of rapamycin signaling independently of insulin receptor. J.
Am. Soc. Nephrol. 27, 1029–1041 (2016).
18. Sedding, D. G. et al. Caveolin-1 facilitates mechanosensitive protein kinase B
(Akt) signaling in vitro and in vivo. Circ. Res. 96, 635–642 (2005).
19. Cohen, A. W., Combs, T. P., Scherer, P. E. & Lisanti, M. P. Role of caveolin
and caveolae in insulin signaling and diabetes. Am. J. Physiol. Endocrinol.
Metab. 285, E1151–E1160 (2003).
20. Razani, B. et al. Caveolin-1-deﬁcient mice are lean, resistant to diet-induced
obesity, and show hypertriglyceridemia with adipocyte abnormalities. J. Biol.
Chem. 277, 8635–8647 (2002).
21. Lee, J. A. et al. Methyl-beta-cyclodextrin up-regulates collagen I expression in
chronologically-aged skin via its anti-caveolin-1 activity. Oncotarget 6,
1942–1953 (2015).
22. Moeller, M. J., Sanden, S. K., Sooﬁ, A., Wiggins, R. C. & Holzman, L. B.
Podocyte-speciﬁc expression of cre recombinase in transgenic mice. Genesis
(Landes Bioscience, Austin, 2000) 35, 39–42 (2003). https://www.ncbi.nlm.nih.
gov/books/NBK25446/
23. Kinoshita, T. & Fujita, M. Biosynthesis of GPI-anchored proteins: special
emphasis on GPI lipid remodeling. J. Lipid Res. 57, 6–24 (2016).
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10584-4
14 NATURE COMMUNICATIONS |         (2019) 10:2692 | https://doi.org/10.1038/s41467-019-10584-4 | www.nature.com/naturecommunications
24. Ahmad, A. et al. Sphingomyelinase-like phosphodiesterase 3b mediates
radiation-induced damage of renal podocytes. FASEB J. 31, 771–780 (2017).
25. Bajwa, A. et al. Sphingosine Kinase 2 deﬁciency attenuates kidney ﬁbrosis via
IFN-gamma. J. Am. Soc. Nephrol. 28, 1145–1161 (2017).
26. Gómez-Muñoz, A. G. P., Granado, M. H., Arana, L., & Ouro, A. Ceramide 1-
phosphate in cell survival and inﬂammatory signaling. In Shingolipids as
Signaling and Regulatory Molecules (ed. Chalfant, C. E. & Poeta, M.) Landes
Bioscience (2000–2013).
27. Gomez-Munoz, A. Ceramide 1-phosphate/ceramide, a switch between life and
death. Biochim. Biophys. Acta 1758, 2049–2056 (2006).
28. Hait, N. C. & Maiti, A. The role of sphingosine-1-phosphate and ceramide-1-
phosphate in inﬂammation and cancer. Mediators Inﬂamm. 2017, 4806541
(2017).
29. Kim, C. H. et al. Conditioning for hematopoietic transplantation activates the
complement cascade and induces a proteolytic environment in bone marrow:
a novel role for bioactive lipids and soluble C5b-C9 as homing factors.
Leukemia 26, 106–116 (2012).
30. Gangoiti, P. et al. Ceramide 1-phosphate stimulates macrophage proliferation
through activation of the PI3-kinase/PKB, JNK and ERK1/2 pathways. Cell.
Signal. 20, 726–736 (2008).
31. Chaurasia, B. et al. Adipocyte ceramides regulate subcutaneous adipose
browning, inﬂammation, and metabolism. Cell Metab. 24, 820–834 (2016).
32. Summers, S. A. Sphingolipids and insulin resistance: the ﬁve Ws. Curr. Opin.
Lipidol. 21, 128–135 (2010).
33. Meikle, P. J. & Summers, S. A. Sphingolipids and phospholipids in insulin
resistance and related metabolic disorders. Nat. Rev. Endocrinol. 13, 79–91 (2017).
34. Chavez, J. A. et al. A role for ceramide, but not diacylglycerol, in the
antagonism of insulin signal transduction by saturated fatty acids. J. Biol.
Chem. 278, 10297–10303 (2003).
35. Chavez, J. A., Holland, W. L., Bar, J., Sandhoff, K. & Summers, S. A. Acid
ceramidase overexpression prevents the inhibitory effects of saturated fatty
acids on insulin signaling. J. Biol. Chem. 280, 20148–20153 (2005).
36. Holland, W. L. et al. Inhibition of ceramide synthesis ameliorates
glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell
Metab. 5, 167–179 (2007).
37. Yamamoto, M. et al. Caveolin is an activator of insulin receptor signaling. J.
Biol. Chem. 273, 26962–26968 (1998).
38. Van Krieken, R. & Krepinsky, J. C. Caveolin-1 in the pathogenesis of diabetic
nephropathy: potential therapeutic target? Curr. Diabetes Rep. 17, 19 (2017).
39. Lee, Y. D., Yoon, S. H., Ji, E. & Kim, H. H. Caveolin-1 regulates osteoclast
differentiation by suppressing cFms degradation. Exp. Mol. Med. 47, e192 (2015).
40. Perreault, L. et al. Intracellular localization of diacylglycerols and
sphingolipids inﬂuences insulin sensitivity and mitochondrial function in
human skeletal muscle. JCI Insight 3, e96805 (2018).
41. Lee, S. Y. et al. Adipocyte-speciﬁc deﬁciency of de novo sphingolipid biosynthesis
leads to lipodystrophy and insulin resistance. Diabetes 66, 2596–2609 (2017).
42. Turinsky, J., O’Sullivan, D. M. & Bayly, B. P. 1,2-Diacylglycerol and ceramide
levels in insulin-resistant tissues of the rat in vivo. J. Biol. Chem. 265,
16880–16885 (1990).
43. Adams, J. M. 2nd et al. Ceramide content is increased in skeletal muscle from
obese insulin-resistant humans. Diabetes 53, 25–31 (2004).
44. Stratford, S., Hoehn, K. L., Liu, F. & Summers, S. A. Regulation of insulin
action by ceramide: dual mechanisms linking ceramide accumulation to the
inhibition of Akt/protein kinase B. J. Biol. Chem. 279, 36608–36615 (2004).
45. He, X., Huang, Y., Li, B., Gong, C. X. & Schuchman, E. H. Deregulation of
sphingolipid metabolism in Alzheimer’s disease. Neurobiol. Aging 31, 398–408
(2010).
46. Pralhada Rao, R. et al. Sphingolipid metabolic pathway: an overview of major
roles played in human diseases. J. Lipids 2013, 178910 (2013).
47. Ogretmen, B. Sphingolipids in cancer: regulation of pathogenesis and therapy.
FEBS Lett. 580, 5467–5476 (2006).
48. Ogretmen, B. Sphingolipid metabolism in cancer signalling and therapy. Nat.
Rev. Cancer 18, 33–50 (2018).
49. Marﬁa, G. et al. Autocrine/paracrine sphingosine-1-phosphate fuels proliferative
and stemness qualities of glioblastoma stem cells. Glia 62, 1968–1981 (2014).
50. Natarajan, V. et al. Sphingosine-1-phosphate, FTY720, and sphingosine-1-
phosphate receptors in the pathobiology of acute lung injury. Am. J. Respir.
Cell Mol. Biol. 49, 6–17 (2013).
51. Baudiß, K. C1P Attenuates lipopolysaccharide-induced acute lung injury by
preventing NF-κB activation in neutrophils. J. Immunol. (Baltimore, MD:
1950) 196, 2319–2326 (2016).
52. Sivasubramanian, M., Kanagaraj, N., Dheen, S. T. & Tay, S. S. Sphingosine
kinase 2 and sphingosine-1-phosphate promotes mitochondrial function in
dopaminergic neurons of mouse model of Parkinson’s disease and in MPP
+-treated MN9D cells in vitro. Neuroscience 290, 636–648 (2015).
53. Rivera, I. G. et al. Ceramide 1-phosphate regulates cell migration and
invasion of human pancreatic cancer cells. Biochem. Pharmacol. 102, 107–119
(2016).
54. Mitsutake, S. et al. Ceramide kinase is a mediator of calcium-dependent
degranulation in mast cells. J. Biol. Chem. 279, 17570–17577 (2004).
55. Graf, C. et al. Neutropenia with impaired immune response to Streptococcus
pneumoniae in ceramide kinase-deﬁcient mice. J. Immunol. (Baltimore, MD:
1950) 180, 3457–3466 (2008).
56. Saleem, M. A. et al. A conditionally immortalized human podocyte cell line
demonstrating nephrin and podocin expression. J. Am. Soc. Nephrol. 13,
630–638 (2002).
57. Granado, M. H. et al. Ceramide 1-phosphate (C1P) promotes cell migration
Involvement of a speciﬁc C1P receptor. Cell. Signal. 21, 405–412 (2009).
58. Bielawski, J., Szulc, Z. M., Hannun, Y. A. & Bielawska, A. Simultaneous
quantitative analysis of bioactive sphingolipids by high-performance liquid
chromatography-tandem mass spectrometry. Methods 39, 82–91 (2006).
59. Boudker, O. & Futerman, A. H. Detection and characterization of ceramide-1-
phosphate phosphatase activity in rat liver plasma membrane. J. Biol. Chem.
268, 22150–22155 (1993).
60. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29,
15–21 (2013).
61. Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor
package for differential expression analysis of digital gene expression data.
Bioinformatics 26, 139–140 (2010).
62. Asanuma, K. et al. Synaptopodin regulates the actin-bundling activity of alpha-
actinin in an isoform-speciﬁc manner. J. Clin. Investig. 115, 1188–1198 (2005).
63. Farley, F. W., Soriano, P., Steffen, L. S. & Dymecki, S. M. Widespread
recombinase expression using FLPeR (ﬂipper) mice. Genes (New York, NY:
2000) 28, 106–110 (2000).
64. Montes, G. S. Structural biology of the ﬁbres of the collagenous and elastic
systems. Cell Biol. Int. 20, 15–27 (1996).
65. Crowley, S. D. et al. Glomerular type 1 angiotensin receptors augment kidney
injury and inﬂammation in murine autoimmune nephritis. J. Clin. Investig.
119, 943–953 (2009).
66. Wei, C. et al. Circulating urokinase receptor as a cause of focal segmental
glomerulosclerosis. Nat. Med. 17, 952–960 (2011).
67. Choudhary, V., Ojha, N., Golden, A. & Prinz, W. A. A conserved family of
proteins facilitates nascent lipid droplet budding from the ER. J. Cell Biol. 211,
261–271 (2015).
68. van den Berg, J. G., van den Bergh Weerman, M. A., Assmann, K. J., Weening, J.
J. & Florquin, S. Podocyte foot process effacement is not correlated with the level
of proteinuria in human glomerulopathies. Kidney Int. 66, 1901–1906 (2004).
69. Takahashi, N., Boysen, G., Li, F., Li, Y. & Swenberg, J. A. Tandem mass
spectrometry measurements of creatinine in mouse plasma and urine for
determining glomerular ﬁltration rate. Kidney Int. 71, 266–271 (2007).
70. McCloy, R. A. et al. Partial inhibition of Cdk1 in G 2 phase overrides the SAC
and decouples mitotic events. Cell Cycle 13, 1400–1412 (2014).
Acknowledgements
A.F. and S.M. are supported by the NIH grants DK104753, DK11759 and CA227493. A.F. is
supported by the NIH grants DK090316, U24DK076169, U54DK083912, UM1DK100846,
and 1UL1TR000460. A.F., S.M., C.F. are supported by Hoffman-La Roche. G.M.D. is
supported by a Predoctoral Fellowship of the American Heart Association
(16PRE30200010). JJK is supported by NRSA Post-doctoral fellowship from NIH/NIDDK
(F32DK115109). We thank Dr. Chalfant for his suggestions in the design of exogenous C1P
experiments in vivo. We thank Dr. Heinz the CeMM Research Center for Molecular
Medicine of the Austrian Academy of Sciences for a kind gift of HA-tagged human wildtype
and mutant SMPDL3b constructs. We would like to acknowledge the skilled assistance of
the Flow Cytometry Shared Resource and the Analytical Imaging Shared Resource of the
Sylvester Comprehensive Cancer Center at the University of Miami, Miller School of
Medicine, for the provision of the sophisticated ﬂuorescence analysis.
Author contributions
A.M. performed the in vitro and in vivo experiments, analyzed the data, and wrote
methods and results of the manuscript. S.K.M. prepared material for illumina sequencing
RNA data analysis, analyzed presence of enriched functional-related gene groups, per-
formed endogenous co-IP experiments, and performed some of the in vivo experiments.
G.M.D. performed WT1 histological staining and some in vitro experiments. J.M. per-
formed PSR histological staining and analysis and some in vitro experiments. T.H.Y.
initialized the characterization of the podocyte-speciﬁc Smpdl3b knockout mice colony.
E.R.-G. and I.D.Z. performed C6 ceramide production assay in HEK293 cells and in
podocytes using puriﬁed SMPDL3b protein. J.V.S., C.G.H., C.P., M.G., A.S., J.J.K. per-
formed some of the in vitro experiments. J.B. and I.V. performed genotyping procedures
and some of the in vitro experiments. C.F. designed some of the immunoprecipitation
experiments. Y.Z. and A.J.M. designed experiments related to sphingolipid analysis. Y.Z.
analyzed some of the mass spec data. I.L. designed and provided human insulin receptor
isoforms plasmids. G.W.B. conceived one of the techniques utilized. A.H.F. designed C6
ceramide production experiments. L.B. evaluated kidney tissue slides for histopathology.
Y.I. and R.I. performed TEM experiments. S.M. and A.F. conceived the project, designed
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10584-4 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:2692 | https://doi.org/10.1038/s41467-019-10584-4 |www.nature.com/naturecommunications 15
and supervised the study, analyzed the data, and edited the manuscript. A.F. wrote
introduction and discussion of the manuscript, she is the guarantor of this work and, as
such, had full access to all the data in the study and takes responsibility for the integrity
of the data and the accuracy of the data analysis.
Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-
019-10584-4.
Competing interests: G.W.B., A.F., and S.M. are inventors on pending or issued patents
(US10,183,038, US10,052,345) aimed to diagnose or treat proteinuric renal diseases. They
stand to gain royalties from their future commercialization. A.F. is Chief Scientiﬁc Ofﬁcer
of L&F Health LLC and is consultant for Variant Pharmaceutical. Variant
Pharmaceuticals, Inc. has licensed worldwide rights to develop and commercialize
hydroxypropyl-beta-cyclodextrin for treatment of kidney disease from L&F Research. S.
M. holds equity interest in a company presently commercializing the form of
cyclodextrin referenced in this paper. The patent associated with the use of
hydroxypropyl-beta-cyclodextrin is published under US10,195,227. A.F. is Chief Medical
Ofﬁcer of LipoNexT, LLC. The remaining authors delare no competing interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Peer review information: Nature Communications thanks the anonymous reviewers
for their contribution to the peer review of this work. Peer reviewer reports are
?available.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2019
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10584-4
16 NATURE COMMUNICATIONS |         (2019) 10:2692 | https://doi.org/10.1038/s41467-019-10584-4 | www.nature.com/naturecommunications
